New Immunotherapy Drug ASITI-201 Begins First Human Trial for Type 1 Diabetes

Researchers at the University of Queensland are recruiting participants for the first human trial of an immunotherapy designed to protect insulin-producing cells by rebalancing the immune system.

News report, corroborated with 1 indexed study

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

ASITI-201 is an immunotherapy combining a pancreatic protein with vitamin D, designed to calm the immune response that attacks insulin-producing cells
The trial will recruit five adults diagnosed with type 1 diabetes within the last five years, marking the first time this drug will be tested in humans
The goal is to preserve pancreatic function and reduce the amount of insulin participants need to inject
This represents a shift from current treatment, which focuses on insulin replacement rather than addressing the underlying immune problem

A New Approach to Type 1 Diabetes

In type 1 diabetes, the immune system mistakenly attacks and destroys beta cells—the insulin-producing cells in the pancreas. Currently, the only available treatment is insulin replacement therapy. Scientists at the University of Queensland are taking a different approach with ASITI-201, an immunotherapy designed to address the root cause: the misdirected immune response.

According to Professor Ranjeny Thomas, the lead researcher, "In people with type 1 diabetes, the immune system starts to recognise pancreatic cells as something it needs to attack." The new drug works by using the immune system's own healing ability to rebalance the response.

How ASITI-201 Works

ASITI-201 combines two key components: a protein derived from the pancreas and vitamin D. Together, these are designed to calm the immune response and protect insulin-producing cells from further damage.

Dr Aakansha Zala, co-author of the research, explained that the drug candidate aims to "preserve as much pancreatic function for as long as possible in people recently diagnosed with type 1 diabetes, to reduce the amount of insulin they need to administer."

The First Human Trial

The trial is recruiting five adults over 18 years old who have been diagnosed with type 1 diabetes within the last five years. The study will take place at the Translational Research Institute's Clinical Research Facility at Brisbane's Princess Alexandra Hospital.

Researchers will examine whether ASITI-201 changes the immune system in the way they predict. This first-in-human trial represents an important step in understanding whether the therapy is safe and effective before larger studies can be considered.

Evidence label

Origin: diabetes.co.uk (News report). Evidence: News report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.